Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaVitaMEX:DVA 75 5-Year Yield-on-Cost % is 0.00 as of Jul. 24, 2026. GuruFocus rates MEX:DVA with a GF Score™ of 75/100 and a GF Value™ of MXN2,511.22 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 277 Healthcare Providers & Services companies, DaVita ranks worse than 361010.47% on this metric.
DaVita's yield on cost for the quarter that ended in Mar. 2026 was 0.00.
The historical rank and industry rank for DaVita's 5-Year Yield-on-Cost % or its related term are showing as below:
MEX:DVA's 5-Year Yield-on-Cost % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.9 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
DaVita 5-Year Yield-on-Cost % Related Terms
MEX:DVA vs THC, EHC, ENSG: 5-Year Yield-on-Cost % Comparison
For the Medical Care Facilities subindustry, DaVita's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where DaVita's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of DaVita is calculated as
DaVita (MEX:DVA) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DaVita and its competitors. According to the industry distribution chart, DaVita ranks #999999 out of 277 companies in the Healthcare Providers & Services industry.
Is DaVita's 5-Year Yield-on-Cost % too high?
DaVita's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, DaVita ranks #999999 out of 277 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, DaVita has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's 5-Year Yield-on-Cost % compare to THC and EHC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #999999 out of 277 companies for 5-Year Yield-on-Cost %. This places DaVita in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.90, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on DaVita and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (MEX:DVA) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN2,511.22, compared to a current price of MXN3,358.09 — trading 33.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. DaVita's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For DaVita (MEX:DVA), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (MEX:DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of MXN3,358.09 is trading 33.7% above its estimated GF Value™ of MXN2,511.22.
GuruFocus considers DaVita to be Significantly Overvalued.
Key valuation signals for MEX:DVA:
5-Year Yield-on-Cost %: 0.00
GF Value™: MXN2,511.22 vs. price of MXN3,358.09 (33.7% above fair value)
No single metric tells the full story. See the MEX:DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
75GF Score
Get the complete analysis for MEX:DVA
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DVA has been successfully added to your 
